Baird Maintains an 'Outperform' on Pharmasset (VRUS); First Impression: Positive for Both Companies and the Space

Baird maintains an 'Outperform' on Pharmasset (NASDAQ: VRUS) price target raised from $88 to $137.

Baird analyst says, "Our base case is this goes through, so we will revisit our VRUS rating accordingly. We view this as a strategic positive for Gilead (Nasdaq: GILD) too, which is paying a full but fair price and one the VRUS model supported with continued clinical success, broad populations, and economics--all area where we and the Street have had high conviction. Consolidation in HCV continues, and the short list includes Outperform-rated Inhibitex (Nasdaq: INHX) and Achillion Pharmaceuticals (Nasdaq: ACHN)."

For an analyst ratings summary and ratings history on Pharmasset click here. For more ratings news on Pharmasset click here.

Shares of Pharmasset closed at $72.67 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• William Blair Downgrades Enovix Corporation (ENVX) to Market Perform
• Yum! Brands (YUM) PT Lowered to $180 at Argus
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation